The U.S. Food and Drug Administration (FDA) has approved Soolantra (ivermectin) Cream 1% for the treatment of rosacea, a condition that may include inflammatory lesions, bumps, pimples, and redness.  Rosacea is a common, but often misunderstood, skin disorder affecting 16 million Americans, particularly ages 30 and older. The cause of rosacea is unknown, but research suggests that there are multiple triggers.  Some triggers include the sun, alcohol, spicy food, and exercise.  Adam Hessel, M.D., a Board Certified Dermatologist at Buckeye Dermatology in Dublin Ohio, said, “Rosacea is a very common problem in the Columbus and Central Ohio areas, and a new topical medication to treat rosacea is a very welcome addition because some patients with rosacea do not improve with the current treatments available.”

Recent research suggests that generally harmless microscopic Demodex mites may also be a culprit. These mites are normally present on everyone’s skin, but people with rosacea have greater numbers on their faces.  Dr. Adam Hessel added, “Soolantra cream contains ivermectin, which reduces the quantity of demodex mites on the skin.”  See the Columbus Medical News video interview with Dr. Hessel about this new treatment for rosacea.

For More Information:

http://rosacea-support.org/galderma-announces-approval-of-soolantra.html

http://www.buckeyedermatology.com/adam-b-hessel.html

https://www.youtube.com/watch?v=dwpHa3ZOFcY